PhRMA says 52% of U.S. pharmacies and health care providers profits' from reimbursement for administering brand-name prescription drugs now comes through participation in the 340B program. The AHA calls the finding an example of drug companies deflecting attention away from the high prices they set.

PhRMA Says More than Half of Pharmacy and Provider Profits on Brand Drug Sales Come Through 340B

More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of the $24.7 billion they took in 2013, according to a new drug industry-funded study.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report